


the fungicidal breakthrough


Scanning Electron Microscopic photographs of *Candida albicans* before and after treatment with miconazole.



1. Untreated cells appear as isolated yeast forms in an oval shape and with a smooth surface showing the formation of polar buds (pb).



2. Upon exposure to a fungistatic dose (10^{-7} M) of miconazole the cells tend to cluster. Budding becomes disorganized with visible budding scars (bs) that are randomly distributed over the surface of the cells.



3. Treatment with a fungicidal dose of miconazole causes the cell wall (cw) to burst. Vesicles of cytoplasm disintegrate and adhere to the surface of yet unbroken cells (cpr). (The interior of the cells is completely lytic).



the standard fungicidal treatment

Daktarin

miconazole nitrate 2 % w/w

*highly effective
in all fungal infections*

further information available on request from:



Janssen Pharmaceutica
2340 Beerse, Belgium.

or from:
Janssen Pharmaceutical Ltd.
Janssen House, Marlow, Bucks.
PL/0242/0016, 17, 47, 48, 52

Trade Marks: Brentan in Denmark and Spain, Daktar in Germany, Daktarin in all other countries.

WHY NOT SUBSCRIBE TO THE SPECIALIST JOURNALS PUBLISHED BY THE BMA:—A SELECTION INCLUDES

Archives of Disease in Childhood, British Heart Journal, British Journal of Ophthalmology, Gut, Journal of Clinical Pathology & Journal of Neurology, Neurosurgery & Psychiatry.

FULL DETAILS OF SUBSCRIPTION RATES FROM BMA SPECIALIST PUBLICATIONS: BMA HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR
TELEPHONE 01-387 4499 EXT. 309.

Reduced Subscription Rates to BMA Specialist Journals for Junior Hospital Doctors Residents and Interns...

BMA Specialist Journals are now available to junior doctors in all parts of the world for a maximum of four consecutive years at REDUCED Annual Subscription Rates. Thereafter, or when reaching consultant status, this special offer will no longer apply.

The following subscription rates apply for 1979:

	REDUCED RATE		Full Rate	
	Inland £	Abroad US\$	Inland £	Abroad US\$
<i>Published Monthly</i>				
Archives of Disease in Childhood.....	17.00	40.00	28.00	65.50
British Heart Journal.....				
British Journal of Ophthalmology.....				
Gut.....				
Journal of Neurology, Neurosurgery and Psychiatry.....				
Cardiovascular Research.....	18.00	36.00	30.00	60.00
Journal of Clinical Pathology.....	18.00	42.00	30.00	70.50
<i>Published six times a year</i>				
Annals of the Rheumatic Diseases.....	13.00	30.00	21.00	49.00
British Journal of Venereal Diseases.....				
Journal of Medical Genetics.....				
Thorax.....				
<i>Published Quarterly</i>				
British Journal of Industrial Medicine.....	9.00	19.00	14.00	32.00
Epidemiology and Community Health.....				

ORDER FORM

To: BMA Publications, BMA House, Tavistock Square,
London WC1H 9JR

Please enter my subscription to:

at the REDUCED RATE of: Inland £..... Abroad US\$.....

My remittance for is enclosed


NAME.....

ADDRESS.....

To be completed by Consultant

I hereby confirm that the above mentioned doctor is a member of the junior hospital staff/resident/intern at

..... Signed.....



Simply right for the job


Lopresor[®]

metoprolol
tartrate for hypertension

Efficacy—Tolerability— β_1 Selectivity—Simple dosage regime:
the essentials of Lopresor simplicity in hypertension



Lopresor prescribing data: Presentation: Lopresor (metoprolol tartrate) as 50mg and 100mg tablets. Indications: Hypertension and angina pectoris. Dosage: *Hypertension*: Initially one 100mg tablet morning and evening. Doses of 100-200mg twice daily may subsequently be prescribed depending upon response. The total daily dose of Lopresor may be given as a single dose if required. Where there has been lack of response to previous therapy, Lopresor may be added to the regimen with the appropriate adjustment of the previous therapy where necessary. *Angina pectoris*: One or two 50mg tablets, twice or three times daily. Contraindications: Atrioventricular block, digitalis-refractory heart failure, severe bradycardia, cardiogenic shock. Precautions: Lopresor has proved safe in a large number of asthmatic patients; although it is a selective beta-blocker it is prudent to exercise care in the treatment of patients with chronic obstructive pulmonary disease. The dosage of any adrenergic bronchodilators may require adjustment. As with other beta-blockers, Lopresor should not be given to patients with cardiac decompensation unless concomitantly treated with digitalis and/or diuretics. It may be necessary to adjust the dose of the hypoglycaemic agent in labile and insulin-dependent diabetes. Lopresor therapy should be brought to the attention of the anaesthetist prior to general anaesthesia. As a result of animal studies in the rat and rabbit there is no reason to believe that Lopresor is, or maybe, teratogenic in humans. However, the administration of Lopresor during pregnancy, as with other drugs, is advised only if there are compelling reasons. Side-effects: Slight gastro-intestinal discomfort and disturbance of sleep pattern occasionally occur. In most cases these effects have been transient, or have disappeared after a reduction in dosage. Further information: Because of its cardioselectivity, Lopresor can be administered even to patients with obstructive respiratory disorders, provided adequate precautions are taken. Legal category: Prescription only. Basic NHS price: 50mg. Packs of 100 tablets £4.20. 100mg. Packs of 100 tablets £7.80. 100mg Calendar Packs of 56 tablets £4.37. Product licence numbers: Lopresor 50mg tablets PL0001/0065. Lopresor 100mg tablets PL0001/0066 Product licence holder: Geigy Pharmaceuticals, Macclesfield, Cheshire.



now available in
calendar packs